Durable Response of Leptomeningeal Disease With Osimertinib and Pemetrexed in EGFR -Mutated Metastatic NSCLC: A Case Report.
- Resource Type
- Report
- Authors
- Merkhofer CM; Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, Washington.; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.; Baik CS; Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, Washington.; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
- Source
- Publisher: Elsevier Inc Country of Publication: United States NLM ID: 101769967 Publication Model: eCollection Cited Medium: Internet ISSN: 2666-3643 (Electronic) Linking ISSN: 26663643 NLM ISO Abbreviation: JTO Clin Res Rep Subsets: PubMed not MEDLINE
- Subject
- Language
- English
Optimal management of EGFR -mutated NSCLC with leptomeningeal (LM) disease progression through EGFR tyrosine kinase inhibitor remains unclear. We present a 39-year-old man with EGFR -mutated NSCLC and LM disease progression through osimertinib 80 mg daily, with subsequent durable radiographic and symptomatic response to systemic pemetrexed in combination with osimertinib. This builds on the limited data evaluating LM disease response to systemic pemetrexed and lends further support to consideration of this treatment strategy.
(© 2021 The Authors.)